Mergers & AcquisitionsBy The Online Investor Staff, updated Sat., Sep. 19, 8:26 AM
|This Slide: #66 of 100|
Slide #66. Sorrento Therapeutics, Inc. — SmartPharm Therapeutics, Inc.
Sorrento Therapeutics, Inc. (NASDAQ:SRNE)
SmartPharm Therapeutics, Inc.
Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") and SmartPharm Therapeutics, Inc. ("SmartPharm") announced today that Sorrento has completed the acquisition of SmartPharm, a gene-encoded protein therapeutics company developing non-viral DNA and RNA gene delivery platforms for COVID-19 and rare diseases with broad potential application in enhancing any antibody-centric therapeutics.
Sorrento Therapeutics is a clinical stage and commercial biopharma company focused on delivering therapies to patients and their families. Co. has two segments: The Sorrento Therapeutics segment, which is organized around its Immune-Oncology therapeutic area, using its proprietary G-MAB antibody library and targeted delivery modalities to generate the next generation of cancer therapeutics. These modalities include proprietary chimeric antigen receptor T-cell therapy, dimeric antigen receptor T-cell therapy, antibody drug conjugates as well as bispecific antibody approaches. The Scilex segment is mainly organized around Co.'s non-opioid pain management operations.
SRNE SEC Filing Email Alerts Service
Open the SRNE Page at The Online Investor »
Strong Buy (4.00 out of 4)
(ranked higher than approx. 82% of all stocks covered)
Based on Zacks ABR data;
powered by Xignite